Ignite Creation Date:
2024-05-06 @ 3:02 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04504279
Status:
COMPLETED
Last Update Posted:
2021-09-16
First Post:
2020-08-05
Brief Title:
Evaluation of FB-401 in Children Adolescents and Adults 2 Years and Older With Mild to Moderate Atopic Dermatitis
Sponsor:
Forte Biosciences Inc
Organization:
Forte Biosciences Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Multicenter 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children Adolescent and Adult Subjects Ages 2 Years and Older With Mild to Moderate Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis FB-401 will be applied topically for 16 weeks and progress will be assessed by assessment of the skin and patient reports
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None